Celgene’s recently approved Otezla is a new medication for the treatment of psoriatic arthritis.
Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP).
Celgene recently selected a limited number of specialty pharmacies to distribute Otezla, including: Diplomat, Avella Specialty Pharmacy, ReCept Pharmacy, and CareMed Pharmaceutical Services.
Celgene’s new psoriatic arthritis drug Otezla will be competing against current offerings from AbbVie , Johnson & Johnson, and Amgen.
Otezla is taken orally, giving Celgene a distinct advantage in the market.